Stock Events

Precigen 

$1.36
41
+$0.02+1.49% Friday 20:00

Statistics

Day High
1.37
Day Low
1.34
52W High
1.88
52W Low
0.84
Volume
422,809
Avg. Volume
677,652
Mkt Cap
343.29M
P/E Ratio
-3.5
Dividend Yield
-
Dividend
-

Earnings

14MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.13
0.06
0.25
0.44
Expected EPS
-0.09
Actual EPS
-0.1

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PGEN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.69B
CRISPR Therapeutics is a competitor because it focuses on gene editing technologies, similar to Precigen's gene and cell therapy work.
Editas Medicine
EDIT
Mkt Cap463M
Editas Medicine operates in the gene editing space, directly competing with Precigen's efforts in developing gene therapies.
Intellia Therapeutics
NTLA
Mkt Cap2.4B
Intellia Therapeutics is involved in CRISPR/Cas9 gene editing, a similar field to Precigen's gene therapy and editing technologies.
Sangamo Therapeutics
SGMO
Mkt Cap123.51M
Sangamo Therapeutics competes with Precigen in the development of genomic therapies, including gene editing and gene therapy.
Bluebird bio
BLUE
Mkt Cap105.66M
bluebird bio is a competitor because it develops gene therapies for genetic diseases and cancer, overlapping with Precigen's therapeutic areas.
Adverum Biotechnologies
ADVM
Mkt Cap157.75M
Adverum Biotechnologies is in the field of gene therapy, focusing on ocular and rare diseases, competing with Precigen's gene therapy efforts.
Biomarin Pharmaceutical
BMRN
Mkt Cap14.34B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap18.69B
Alnylam Pharmaceuticals focuses on RNAi (RNA interference) therapeutics, which is a different but competing approach to Precigen's gene and cell therapy techniques.
Beam Therapeutics
BEAM
Mkt Cap2B
Beam Therapeutics competes with Precigen through its development of precision genetic medicines using base editing, a novel form of gene editing.
Fate Therapeutics
FATE
Mkt Cap400.69M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, competing with Precigen's work in cell therapy.

Analyst Ratings

9$Average Price Target
The highest estimate is $14.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
20%
Sell
20%

About

Health Technology
Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Show more...
CEO
Helen Sabzevari
Employees
202
Country
US
ISIN
US74017N1054
WKN
000A2PZG1

Listings